首页 > 市场调查报告书 > 医疗设备

市场调查报告书

商品编码

1345388

全球脑植入市场 - 2023-2030

Global Brain Implants Market - 2023-2030

出版日期: 2023年09月06日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

全球脑植入市场在2022 年达到53 亿美元，预计到2030 年将实现利润丰厚的增长，达到108 亿美元。全球脑植入市场预计在预测期内（2023-2023 年）复合年增长率为9.5% 2030）。

大脑植入物在各个领域都具有重要意义，因为它们具有直接与大脑交互并实现神经活动与外部设备之间通信的潜力。无线技术的进步使大脑植入物能够与外部设备进行通信，而无需物理连接器。这一趋势旨在提高使用大脑植入物的舒适度和舒适度，同时降低感染或与有线连接相关的其他并发症的风险。

此外，神经退行性疾病和精神疾病的数量不断增加，并且对负担得起的、有效的和永久性疗法的需求未得到满足。由于神经外科医生和神经病学诊所不断努力提高人们对脑植入物的认识，脑植入物的市场规模正在不断增长。

动力学

神经系统疾病的患病率不断上升

神经系统疾病的增加有助于市场的扩张。例如，人们可以通过在脑组织中植入电极来刺激或记录来自大脑各个部分的信号。帕金森病经常使用脑植入物进行治疗，特别是深部脑刺激（DBS）。帕金森病是一种神经退行性疾病，其特征是产生多巴胺的脑细胞逐渐丧失。

马达消耗会导致颤抖、僵硬、运动迟缓（运动缓慢）和姿势不稳定等运动症状。帕金森氏症的症状是由异常的大脑活动引起的，而电刺激有助于控制这种异常的大脑活动。因此，帕金森病的增加有助于市场的扩张。

例如，据帕金森基金会称，帕金森病（PD）影响着美国约一百万人。到 2030 年，预计这一数字将达到 120 万。继阿尔茨海默病之后，帕金森病是最常见的神经退行性疾病。在美国，每年有近 90,000 人被诊断出帕金森病。全球有超过 1000 万人患有帕金森病。因此，神经系统疾病的增加有助于市场的扩张。

公司重点发展战略

由于市场对新技术的需求不断增加，与脑植入相关的产品批准、产品发布、合作和收购有所增加。例如，2022年10月，为了更有效地治疗神经系统疾病，神经技术公司Axoft开发的脑机接口（BMI）被指定为FDA突破性设备。该公司筹集了 800 万美元资金，用于支持 FDA 的临床前研究并扩大其“软如大脑”神经植入物的原型。

此外，2023 年 5 月 26 日，埃隆·马斯克 (Elon Musk) 及其神经技术企业 Neuralink 的联合创始人宣布，美国食品和药物管理局已批准该公司开展首次人体临床研究。 The Link 是 Neuralink 正在开发的一种大脑植入物，旨在让严重瘫痪的人仅利用神经信号来操作外部技术。这表明，患有肌萎缩侧索硬化症等晚期退行性疾病的人有一天可能会重新获得用意念打字和移动光标的能力。由于上述因素，市场将在预测期内扩大。

与治疗相关的高成本

大脑植入物的开发和植入成本可能很高。手术治疗、术后护理和未来的小工具更换都包含在价格中。例如，不同的製造商对大脑植入物收取不同的价格。在美国，手术费用（包括植入设备、住院费用和麻醉费）从 35,000 美元到 100,000 美元不等。

获得该技术可能会受到价格的阻碍，特别是对于那些负担不起的人来说。此外，植入大脑需要高度复杂的手术技术，需要经验丰富的神经外科医生和配备尖端设备的手术室。手术、麻醉和术后护理可能会产生巨大的经济费用。因此，上述因素将抑制市场的增长。

Brain implants hold significant importance across various fields due to their potential to interface directly with the brain and enable communication between neural activity and external devices. Advances in wireless technology were enabling brain implants to communicate with external devices without the need for physical connectors. The trend aimed to improve the comfort and comfort of using brain implants while also reducing the risk of infection or other complications associated with wired connections.

In addition, there is an increasing number of neurodegenerative and mental illnesses, as well as an unmet demand for affordable, effective, and permanent therapies. The market size for brain implants is growing as a result of increasing effort being made by neurosurgeons and neurology clinics to increase awareness of brain implants.

Dynamics

The Rising Prevalence of Neurological Diseases

The increase in neurological disorders contributes to the market's expansion. For instance, one can stimulate or record signals from various parts of the brain by implanting electrodes in the brain tissue. Parkinson's disease is frequently treated using brain implants, specifically Deep Brain Stimulation (DBS). Parkinson's disease is a neurodegenerative condition marked by a progressive loss of brain cells that produce dopamine.

Motor symptoms like tremors, stiffness, bradykinesia (slow movement), and postural instability are brought on by this dopamine depletion. The Parkinson's symptoms are caused by aberrant brain activity, which the electrical stimulation helps control. Thus, the rise in Parkinson's disease contributes to the market's expansion.

For instance, according to Parkinson's Foundation, stated that, Parkinson's disease (PD) affects around one million persons in the US. By 2030, it is anticipated that this number would reach 1.2 million. After Alzheimer's disease, Parkinson's disease is the most common neurodegenerative condition. In the United States, PD is yearly diagnosed in close to 90,000 individuals. Over 10 million people worldwide suffer with PD. Thus, the increase in neurological illnesses contributes to the market's expansion.

Key Development Strategies Followed by the Companies

The increase in the product approvals, product launches, collaborations and acquisitions related to brain implants owing to its increasing demand to novel technologies to the market. For instance, in October 2022, in order to more effectively treat neurological illnesses, the brain-machine interface (BMI) developed by the neurotechnology company Axoft was designated an FDA Breakthrough Device. The business raised $8 million in funding to support pre-clinical FDA research and scale up prototypes of its "soft as the brain" neural implants.

Additionally, on May 26, 2023, Elon Musk and his co-founders at the neurotech business Neuralink announced that the Food and Drug Administration had given the company permission to carry out its first in-human clinical investigation. The Link, a brain implant being developed by Neuralink, intends to enable individuals with severe paralysis to operate external technology only utilizing neural signals. This suggests that people with terminal degenerative illnesses like ALS may someday regain the ability to type and move cursors with their minds. Due of the above factors the market will expand in forecast period.

High Cost Associated with the Treatment

Brain implants can be costly to develop and implant. Surgical treatments, post-operative care, and prospective gadget replacements are all included in the price. For instance, different manufacturers charge different prices for brain implants. The price of surgery (including the implanted device, hospital expenses, and anesthesia) can range from $35,000 to $100,000 in the United States.

Access to the technology may be hampered by the price, especially for those who cannot afford it. Additionally, placing brain implants requires highly sophisticated surgical techniques that call for experienced neurosurgeons and an operating theater outfitted with cutting-edge equipment. Surgery, anesthesia, and post-operative care can come at a significant financial expense. Thus above factors will restrain the market growth.

Segment Analysis

The global brain implants market is segmented based ontype, material, application, end user and region.

The Alzheimer's Disease Accounted for Approximately 31.07% of the Brain Implants Market Share

Dementia, a condition marked by memory loss and cognitive decline, is one of the main causes of dementia. ReTypes are needed for diagnosis, treatment, care, and support services for affected people, placing a significant load on healthcare systems. Age is the major risk factor for Alzheimer's disease. A larger portion of the population is at an elevated risk of contracting the disease as the world's population continues to age. An individual's risk increases as they age.

The intricate combination of genetic, environmental, and lifestyle factors affects the risk of Alzheimer's disease. These elements may combine as people get older, raising the risk that they may have the illness. Thus, the increase in the elderly population drives segment growth.

For instance, according to Eurostat, the EU population in January 2022, was estimated to be 446.7 million, out of which 21.1% were Older individuals aged 65 or over indicating an increase of 0.3 percentage points (pp) to the previous year and an increase of 3.1 pp compared with a decade earlier.

In addition, according to a new report by the United Nations (UN), the number of individuals aged 65 years or above globally is anticipated to increase two folds in the next 30 years. The geriatric population is expected to attain 1.6 billion in 2050, making up over 16% of the world population. By thus increasing the geriatric population will drive the segment growth.

Geographical Penetration

North America Accounted for Approximately 42.6% of the Market Share in 2022

The brain implant market is dominated by North America. Due to the regulations that make healthcare inexpensive for the vast majority of the population in the region, the nation's healthcare facilities are of the greatest quality and are accessible to the wide population. The prevalence and incidence of numerous neurological illnesses are rising, which will accelerate the growth of the region.

For instance, according to Alzheimer's Association, more than 6 million Americans of all ages have Alzheimer's. In 2023, there will be 6.7 million Americans 65 and older who have Alzheimer's. 73% of people are 75 years of age or older. The proportion of Americans who have Alzheimer's disease or another kind of dementia will increase along with the size of the population in the United States who are 65 years of age and older. Barring technological advances that prevent or treat Alzheimer's disease, the estimated number of persons aged 65 and older with the condition may increase to 12.7 million by 2050.

Thus, the demand for neurological treatments including brain implants is fueled by the need to identify and treat these diseases, which is anticipated to lead to a growth in the number of product manufacturing companies in the nation. The market in the North American region has grown as a result of the rise in neurological diseases.

Competitive Landscape

The major global players in the brain implants market Medtronic PLC, Boston Scientific Corporation, Renishaw PLC, Synchron Inc, Abbott Laboratories, LivaNova PLC, NeuroPace Inc, Sapiens Neuro, Neuralink, Nexstim and others.

COVID-19 Impact Analysis

The covid has affected negatively due to several factors. The danger of infection is present throughout any surgical operation, including brain implant surgeries. Since COVID-19 is extremely contagious, catching it while having a brain implant could result in serious illness or difficulties.Access to medical care has been hampered throughout numerous locations due to the pandemic.

Due of COVID-19's impact on the healthcare system, people with brain implants may have trouble getting timely treatment or device changes. In many hospitals, brain implant surgery, such as DBS, is an elective surgical procedure, hence the scheduled surgeries have been postponed. When the restrictions were eased, procedures were carried out and patients were advised to maintain their most recent optimal dosing schedule.

By Type

Deep Brain Stimulator
Spinal Cord Stimulator
Vagus Nerve Stimulator

By Material

Silicon
Tungsten
Platinum-iridium
Nanotubes
Others

By Application

Alzheimer's Disease
Parkinson's Disease
Epilepsy
Chronic Pain
Others

By End User

Hospitals
Neurology clinics
Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

Middle East and Africa

Key Developments

In May 2022, in order to allow six severely paralyzed people to operate digital gadgets hands-free and with only their thoughts, Elon Musk's competitor firm Neuralink, Synchron, has started conducting human trials on the subject. The US-based Synchron competes with Elon Musk's Neuralink, which also seeks to let paralyzed people to use computers and phones through its brain activities alone. Both companies create endovascular brain-computer interfaces (BCIs).
In March 2021, one of the largest investments in the European medical nanotechnology sector to date has been made in a collaboration between two Barcelona institutions and the Nanomedicine Lab at The University of Manchester to treat brain disorders such as epilepsy and Parkinson's Disease.
In December 2022, the Eterna spinal cord stimulation (SCS) system from Abbott, the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain, received FDA approval. The only SCS waveform technology with the greatest level of clinical proof (1A evidence), low-dose BurstDR stimulation, is used in Eterna SCS and has been shown to relieve pain 23% more than conventional waveform technology methods.

Why Purchase the Report?

To visualize the global brain implants market segmentation based on type, material, application, end user and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of brain implants market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global brain implants market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by Material
3.3. Snippet by Application
3.4. Snippet by End User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. The rising prevalence of neurological diseases
  - 4.1.1.2. Key Development Strategies Followed by the Companies
- 4.1.2. Restraints
  - 4.1.2.1. High cost associated with the treatment
- 4.1.3. Opportunity
  - 4.1.3.1. New avenues for treating mental health conditions
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. ByType

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 7.1.2. Market Attractiveness Index, By Type
7.2. Deep Brain Stimulator*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Spinal Cord Stimulator
7.4. Vagus Nerve Stimulator

8. ByMaterial

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 8.1.2. Market Attractiveness Index, By Material
8.2. Silicon*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Tungsten
8.4. Platinum-iridium
8.5. Nanotubes
8.6. Others

9. ByApplication

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.1.2. Market Attractiveness Index, By Application
9.2. Alzheimer's Disease l*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Parkinson's Disease
9.4. Epilepsy
9.5. Chronic Pain
9.6. Others

10. ByEnd User

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals *
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Neurology clinics
10.4. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.7.1. U.S.
  - 11.2.7.2. Canada
  - 11.2.7.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.7.1. Germany
  - 11.3.7.2. U.K.
  - 11.3.7.3. France
  - 11.3.7.4. Spain
  - 11.3.7.5. Italy
  - 11.3.7.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.7.1. Brazil
  - 11.4.7.2. Argentina
  - 11.4.7.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.7.1. China
  - 11.5.7.2. India
  - 11.5.7.3. Japan
  - 11.5.7.4. Australia
  - 11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. Medtronic PLC*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Boston Scientific Corporation
13.3. Renishaw PLC
13.4. Synchron Inc
13.5. Abbott Laboratories
13.6. LivaNova PLC
13.7. NeuroPace Inc
13.8. Sapiens Neuro
13.9. Neuralink
13.10. Nexstim

LIST NOT EXHAUSTIVE